Identification and expression of troponin T, a new marker on the surface of cultured tumor endothelial cells by aptamer ligand

Cancer Medicine

Volumn 3, Issue 4, 2014, Pages 825-834

  Ara, Mst Naznin ^a   Hyodo, Mamoru ^a   Ohga, Noritaka ^a   Akiyama, Kosuke ^a   Hida, Kyoko ^a   Hida, Yasuhiro ^b   Shinohara, Nobuo ^b   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; DNA aptamer; MALDI TOF mass spectroscopy; mTECs; Troponin T

Indexed keywords

APTAMER; ARAHH001; BIOTIN; MESSENGER RNA; STREPTAVIDIN; TROPONIN T; UNCLASSIFIED DRUG; PEPTIDE APTAMER; TUMOR MARKER;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTING; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SILVER STAINING; TUMOR CELL; TUMOR ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; CHEMISTRY; COMBINATORIAL CHEMISTRY; METABOLISM; STAINING; TUMOR CELL CULTURE;

ANIMALS; APTAMERS, NUCLEOTIDE; APTAMERS, PEPTIDE; BIOMARKERS, TUMOR; ENDOTHELIAL CELLS; HUMANS; MICE; SELEX APTAMER TECHNIQUE; STAINING AND LABELING; TROPONIN T; TUMOR CELLS, CULTURED;

EID: 84929143120     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.260     Document Type: Article

References (62)

1. Ozier, O., N. Amin, and T. Ideker . 2003. Global architecture of genetic interactions on the protein network. Nat. Biotechnol. 21:490-491.
2. Wu C. C., and J. R. Yates . 2003. The application of mass spectrometry to membrane proteomics. Nat. Biotechnol. 21:262-267.
3. Rifai, N., M. A. Gillette, and S. A. Carr . 2006. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2:971-983.
4. Srinivas, P. R., B. S. Kramer, and S. Srivastava . 2001. Trends in biomarker search for cancer detection. Lancet Oncol. 2:698-704.
5. Folkman, J. 1971. Tumor angiogenesis, therapeutic implications. New Engl. J. Med. 285:1182-1186.
6. Folkman, J. 2007. Angiogenesis, an organizing principle for drug discovery? Nat. Rev. Drug Discov. 2007:273-286.
7. Sessa, C., A. Guibal, G. D. Conte, and C. Ruegg . 2008. Biomarkers of angiogenesis for the development of anti-angiogenic therapies in oncology: tools or decorations? Nat. Clin. Pract. Oncol. 5:378-391.
8. Kerbel, R. S. 2008. Tumor angiogenesis. New Engl. J. Med. 358:2039-2049.
9. Eleanor, B., D. Carson-Walter, N. Watkins, and A. Nanda . 2001. Cell surface endothelial markers are conserved in mice and humans. Cancer Res. 61:6649-6655.
10. Bertolini, F., Y. Shaked, P. Mancuso, and R. Kerbel . 2006. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 6:835-845.
11. Pircher, A., W. Hilbe, I. Heidegger, J. Drevs, A. Tichelli, and M. Medinger . 2011. Biomarkers in tumor angiogenesis and anti-angiogenic therapy. Int. J. Mol. Sci. 12:7077-7099.
12. Hardwick, J. S., Y. Yang, C. Zhang, B. Shi, R. McFall, E. J. Koury, et al. 2005. Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling. Mol. Cancer Ther. 4:413-425.
13. Chen, R., S. Pan, T. A. Brentnall, and R. Aebersold . 2005. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol. Cell. Proteomics 4:523-533.
14. Moulay, A. J. A., and X. U. Ying-jie . 2006. Proteomic technology for biomarker profiling in cancer: an update. J. Zhejiang Univ. Sci B 7:411-420.
15. Shin, B. K., H. Wang, A. M. Yim, F. L. Naour, and F. Brichory . 2003. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J. Biol. Chem. 278:7607-7616.
16. Colas, P., B. Cohen, T. Jessen, I. Grishna, J. McCoy, and R. Brent . 1996. Genetic selection of peptide aptamers that recognize and inhibit cyclin-independent kinase 2. Nature 380:548-550.
17. Hicke, B. J., A. W. Stephens, T. Gould, Y. F. Chang, and C. K. Lynott . 2006. Tumor targeting by an aptamer. J. Nucl. Med. 47:668-678.
18. Ellington, A. D., and J. W. Szostak . 1990. In vitro selection of RNA molecules that binds specific ligands. Nature 346:818-822.
19. Tuerk, C., and L. Gold . 1990. Systemic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510.
20. Song, K., S. Lee, and C. Ban . 2012. Aptamers and their biological applications. Sensors (Basel) 12:612-631.
21. Morris, K. N., K. B. Jensen, C. M. Julin, M. Weil, and L. Gold . 1998. High affinity ligands from in vitro selection, Complex targets. Proc. Natl. Acad. Sci. USA 95:2902-2907.
22. Srisawat, C., and D. R. Engelke . 2010. Selection of RNA aptamers that bind HIV-1 LTR DNA duplexes, strand invaders. Nucleic Acids Res. 38:8306-8315.
23. Bunka, D. H. J., and P. G. Stockley . 2006. Aptamers come of age-at last. Nat. Rev. Microbiol. 4:588-596.
24. Khati, M. 2010. The future of aptamers in medicine. J. Clin. Pathol. 63:480-487.
25. Keefe, A. D., S. Rai, and A. Ellington . 2010. Aptamer as therapeutics. Nat. Rev. Drug Discov. 9:537-550.
26. Tang, Z., D. Shangguan, K. Wang, H. Shi, and K. Sefah . 2007. Selection of aptamers for molecular recognition and characterization of cancer cells. Anal. Chem. 79:4900-4907.
27. Xiao, Z., D. Shangguan, Z. Cao, X. Fang, and W. Tan . 2008. Cell specific internalization study of aptamer from whole cell selection. Chem. Eur. J. 14:1769-1775.
28. Sefah, K., D. Shangguan, X. Xiong, M. B. Donoghue, and W. Tan . 2010. Development of DNA aptamer using cell-SELEX. Nat. Protoc. 2010:1169-1185.
29. Cibiel, A., D. M. Dupont, and F. Duconge . 2011a. Methods to identify aptamers against cell surface biomarkers. Pharmaceutical 4:1216-1235.
30. Mallikaratchy, P., Z. Tang, S. Kwame, L. Meng, D. Shangguan, and W. Tan . 2007. Aptamer directly evolved from live cells recognizes membrane bound immunoglobulin heavy mu chain in Burkits lymphoma cells. Mol. Cell. Proteomics 6:2230-2238.
31. Shangguan, D., Z. Cao, L. Meng, P. Mallikaratchy, K. Sefah, H. Wang, et al. 2008. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J. Proteome Res. 7:2133-2139.
32. Berzovski, M. V., M. Lechmann, M. U. Musheev, T. W. Mak, and S. N. Krylov . 2008. Aptamer-facilitated biomarker discovery (AptaBiD). J. Am. Chem. Soc. 130:971-983.
33. Shi, H. D., D. Z. Tang, D. Y. Kim, D. H. Nie, P. Y. F. Huang, P. X. He, et al. 2010. In vivo fluorescence imaging of tumors using molecular aptamers generated by cell-SELEX. Chem. Asian J. 5:2209-2213.
34. Sefah, K., J. A. Phillips, X. Xiong, L. Meng, S. D. Van, H. Chen, et al. 2009. Nucleic acid aptamers for biosensors, and bio-analytical applications. Analyst 134:1765-1775.
35. Ruckman, J., L. S. Green, J. Beeson, S. Waugh, W. L. Gillette, D. D. Henninger, et al. 1998. 2-Fluropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF 165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273:20556-20567.
36. Ni, X., M. Castanares, A. Mukherjee, and S. E. Lupold . 2011. Nucleic acid aptamers: clinical applications and promising new horizons. Curr. Med. Chem. 18:4206-4214.
37. Soontornworajit, B., and Y. Wang . 2011a. Nucleic acid aptamers for clinical diagnosis: cell detection and molecular imaging. Anal. Bioanal. Chem. 399:1591-1599.
38. Smith, J. E., C. D. Medley, Z. Tang, Z. D. Shangguan, C. Lofton, and W. Tan . 2007. Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Anal. Chem. 79:3075-3082.
39. Medley, C. D., J. E. Smith, Z. Tang, Y. Wu, S. Bamrungsap, and W. Tan . 2008. Gold-nanoparticle based colorimetric assay for the direct detection of cancerous cells. Anal. Chem. 80:1067-1072.
40. Herr, J. K., J. E. Smith, C. D. Medley, D. Shangguan, and W. Tan . 2006. Aptamer-conjugated nano particles for selective collection and detection of cancer cells. Anal. Chem. 78:2918-2924.
41. Marolt, U., A. Cencic, M. Gorenjak, and S. Potrc . 2012. Generating aptamers for cancer diagnosis and therapy. Clin. Exp. Pharmacol. 2:1-8.
42. Soontornworajit, B., and Y. Wang . 2011b. Nucleic acid aptamers for clinical diagnosis: cell detection and molecular imaging. Anal. Bioanal. Chem. 399:1591-1599.
43. Cibiel, A., D. M. Dupont, and F. Duconge . 2011b. Methods to identify aptamers against cell surface biomarkers. Pharmaceuticals 4:1216-1235.
44. Ara, M. N., M. Hyodo, N. Ohga, K. Hida, and H. Harashima . 2012. Development of DNA aptamer against primary cultured tumor endothelial cells by cell-based SELEX method. PLoS ONE 7:e-5.
45. Hida, K., Y. Hida, D. N. Amin, A. F. Flin, D. Panigrahy, C. C. Morton, et al. 2009. Cytogenic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am. J. Pathol. 175:2657-2667.
46. Hida, K., H. Hida, and M. Shindoh . 2008. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci. 99:459-466.
47. Matsuda, K., N. Ohga, Y. Hida, C. Muraki, K. Tsuchiya, T. Kurosu, et al. 2010. Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem. Biophys. Res. Commun. 394:947-954.
48. Hida, K., Y. Hida, D. N. Amin, A. F. Flint, D. Panigrahy C. C. Morton, et al. 2004. Tumor associated endothelial cells with cytogenic abnormalities. Cancer Res. 64:8249-8255.
49. Ellis, L. M., and D. J. Hicklin . 2008. VEGF targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8:579-591.
50. Suzuki, Y., N. Ohga, Y. Morishita, K. Hida, K. Miyazono, and T. Watabe . 2010. BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J. Cell Sci. 123:1684-1692.
51. Hellman, L. M., and M. G. Fried . 2007. Electrophoretic mobility shift assay (EMSA) for detecting protein-nucleic acid interactions. Nat. Protoc. 2:1849-1861.
52. Kurosu, T., N. Ohga, Y. Hida, N. Maishi, K. Akyama, W. Kakuguchi, et al. 2011. HuR keeps an angiogenic switch on by stabilizing mRNA of VEGF and COX-2 in tumor endothelium. Br. J. Cancer 104:819-829.
53. Risnik, V. V., A. D. Verin, and N. B. Gusev . 1985. Comparison of the structure of two cardiac troponin T isoforms. Biochem. J. 225:549-552.
54. Sawyers, C. L. 2008. The cancer biomarker problem. Nature 452:548-552.
55. Babuin, L., and A. S. Jafee . 2005. Troponin: the biomarker of choice for the detection of cardiac injury. Can. Med. Assoc. J. 173:1191-1202.
56. Messner, B., H. M. D. Baum, P. M. D. Fischer, S. M. D. Quasthoff, and D. M. D. Neumeier . 2000. Expression of messenger RNA of the cardiac isoforms of Troponin T and I in myopathic skeletal muscle. Am. J. Clin. Pathol. 114:544-549.
57. Kociol, R. D., P. S. M. Gheorghiade, G. C. Fonarow, C. M. Connor, and G. M. Felker . 2010. Troponin elevation in heart failure: prevalence, mechanisms, and clinical implications. J. Am. Coll. Cardiol. 56:1071-1080.
58. Angelo, L. S., and R. Kurzrock . 2007. Vascular endothelial growth factor and its relationship to inflammatory mediators. Cancer Res. 13:2825-2830.
59. Chung, N. A., C. Lydakis, F. Belgore, A. D. Blann, and G. Y. H. Lip . 2002. Angiogenesis in myocardial infarction: an acute or chronic process? Eur. Heart J. 23:1604-1608.
60. Carmeliet, P. 2005. Angiogenesis in life, disease and medicine. Nature 438:932-936.
61. Coultas, L., K. Chawengsaksophak, and J. Rossant . 2005. Endothelial cells and VEGF in vascular development. Nature 438:937-945.
62. Wu, H., and P. Li . 2008. Proteins expressed on tumor endothelial cells as potential targets for anti-angiogenic therapy. J. Cancer Mol. 4:17-22.